S. Dass

发表

Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2015, Annals of the rheumatic diseases.

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

Development of psoriasis after B cell depletion with rituximab.

P. Emery, E. Vital, S. Dass, 2007, Arthritis and rheumatism.

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2020, Frontiers in Medicine.

Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis

P. Emery, E. Vital, S. Dass, 2006 .

Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis

P. Emery, E. Vital, S. Dass, 2006, Expert opinion on pharmacotherapy.

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

P. Emery, F. Ponchel, C. Pease, 2011, Arthritis and rheumatism.

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2022, Frontiers in Immunology.

Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus.

P. Emery, E. Vital, S. Dass, 2012, Rheumatology.

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial

P. Emery, E. Vital, M. Buch, 2014, Annals of the rheumatic diseases.

Does extremity-MRI improve erosion detection in severely damaged joints? A study of long-standing rheumatoid arthritis using three imaging modalities

P. Emery, P. Conaghan, S. Dass, 2007, Annals of the rheumatic diseases.

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome

P. Emery, C. Pease, Md Yuzaiful Md Yusof, 2022, ACR open rheumatology.

Single-centre experience of refractory rheumatoid arthritis

P. Emery, M. Buch, J. Nam, 2022, Rheumatology advances in practice.

Response to Dr Bredemeier's letter

P. Emery, E. Vital, M. Buch, 2014, Annals of the rheumatic diseases.

OP0238 The Effect of Cyclophosphamide and Rituximab for Remission Induction and Maintenance in Severe Anca-Associated Vasculitis on Immunoglobulin Levels: Repeat Cycles on Clinical Relapse with Rituximab are Associated with Stable IGA and IGG

P. Emery, S. Dass, S. Savic, 2015 .

Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis

P. Emery, E. Vital, Sudipto Das, 2012, Annals of the rheumatic diseases.

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases

P. Emery, E. Hensor, Md Yuzaiful Md Yusof, 2019, Arthritis & rheumatology.

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

P. Emery, E. Vital, D. McGonagle, 2011, Arthritis and rheumatism.

Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.

P. Emery, Md Yuzaiful Md Yusof, L. Garcia-Montoya, 2020, Rheumatology.

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.

Dennis McGonagle, Paul Emery, P. Emery, 2008, Arthritis and rheumatism.

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

P. Emery, S. Rauz, C. Pease, 2008, Annals of the rheumatic diseases.

B cell targets in rheumatoid arthritis

P. Emery, E. Vital, S. Dass, 2009 .

Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2017, Rheumatology.

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.

P. Emery, F. Ponchel, E. Vital, 2010, Arthritis and rheumatism.

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2023, The Lancet Rheumatology.

44. Buerger’s disease with severe eosinophilia and acute critical ischemia

S. Dass, A. Aslam, Mansoor ul haq Keen, 2019, Rheumatology Advances in Practice.

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.

Md Yuzaiful Md Yusof, E. Vital, M. Ehrenstein, 2022, Rheumatology.

101 Safety of Rituximab in Patients with Rheumatoid Arthritis Associated with Bronchiectasis: Results from a Multicentre Cohort

P. Emery, C. Kelly, S. Dass, 2016 .

Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.

P. Emery, Md Yuzaiful Md Yusof, E. Vital, 2020, Rheumatology.

FRI0090 SINGLE CENTRE COHORT OF REFRACTORY RHEUMATOID ARTHRITIS ALSO IDENTIFIES A RARE SUBGROUP OF MULTIPLE TARGETED THERAPY CLASS NON-RESPONSE

P. Emery, M. Buch, J. Nam, 2019, Poster Presentations.

089 Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response

P. Emery, M. Buch, J. Nam, 2019, Rheumatology.

Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al.

P. Emery, F. Ponchel, E. Vital, 2009, Arthritis and rheumatism.

An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial

P. Emery, E. Vital, M. Buch, 2014, Annals of the rheumatic diseases.

60 – B-cell depletion

P. Emery, E. Vital, S. Dass, 2015 .

THU0158 Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre

P. Emery, E. Vital, S. Dass, 2015 .

092. Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre

P. Emery, E. Vital, S. Dass, 2015 .

The time of equipoise on the use of biological DMARDs in for inflammatory arthritis during pregnancy is finally over: a reappraisal of evidence to optimise pregnancy management

M. Clowse, R. Dolhain, S. Dass, 2024, The Lancet Rheumatology.

Poly‐Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes

K. Mankia, R. Wakefield, S. Dass, 2023, Arthritis & rheumatology.